The Human MBNL1 kit is designed for the rapid quantification of Muscleblind-like in cell lysates.
For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
MBNL1 is involved in RNA-protein complexes with MBNL2 and DMPKRNA. In myotonic dystrophy 1 (DM1), known as a progressive neuromuscular disorder, aggregation of the mutant DMPKRNA with protein complexes has been associated to aberrant splicing of the insulin receptor. MBNL1 has been shown to bind CUG repeat sequences on RNA sequences.
Assay Points |
500
|
---|---|
Assay Target Type |
Kit
|
Assay Technology |
HTRF
|
Brand |
HTRF
|
Quantity |
1
|
Shipping Conditions |
Shipped in Dry Ice
|
Therapeutic Area |
Rare Diseases
|
Unit Size |
500 Assay Points
|
Human MBNL1 is measured using a sandwich immunoassay involving two specific anti-MBNL1 antibodies respectively labelled with Europium Cryptate (donor) and d2 (acceptor). The intensity of the signal is proportional to the concentration of human MBNL1 present in the sample.
The MBNL1 assay features a two-plate assay protocol, where cells are plated, stimulated, and lysed in the same culture plate. Lysates are then transferred to the assay plate for the detection of MBNL1. This protocol enables the cells' viability and confluence to be monitored. The antibodies labelled with HTRF fluorophores may be pre-mixed and added in a single dispensing step to further streamline the assay procedure. The assay detection can be run in 96- to 384-well plates by simply resizing each addition volume proportionally.
Discover the versatility and precision of Homogeneous Time-Resolved Fluorescence (HTRF) technology. Our HTRF portfolio offers a...
This guide provides you an overview of HTRF applications in several therapeutic areas.
Are you looking for technical documents related to the product? We have categorized them in dedicated sections below. Explore now.
We are here to answer your questions.